Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 20/20 | 0.80 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2017590 | 0.89 | FFAR2 (0.64) | FFAR2MEN1LMNAKMT2A | |
| SCHEMBL2016728 | 0.88 | FFAR2 (0.65) | FFAR2LMNA | |
| SCHEMBL16369613 | 0.83 | FFAR2 (1.00) | FFAR2MEN1LMNAKMT2A | |
| SCHEMBL16369612 | 0.83 | FFAR2 (1.00) | FFAR2MEN1LMNAKMT2A | |
| SCHEMBL27713666 | 0.79 | FFAR2 (0.71) | FFAR2MEN1LMNAKMT2A | |
| SCHEMBL16369644 | 0.75 | FFAR2 (1.00) | FFAR2MEN1LMNAKMT2A | |
| SCHEMBL2017232 | 0.75 | CDK2 (0.50) | FFAR2 | |
| SCHEMBL16369642 | 0.75 | FFAR2 (1.00) | FFAR2MEN1LMNAKMT2A | |
| SCHEMBL2753331 | 0.74 | MEN1 (0.72) | FFAR2MEN1LMNAKMT2A | |
| SCHEMBL2018982 | 0.74 | HDAC1 (0.76) | FFAR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221773-B2 | Benzamide derivatives | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2015-12-29 | — | — | US | claimed |
| US-20130045982-A1 | BENZAMIDE DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2013-02-21 | — | — | US | claimed |
| WO-2011079036-A1 | BENZAMIDE DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2011-06-30 | — | — | WO | claimed |
| US-9221773-B2 | Benzamide derivatives | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221773-B2 | Benzamide derivatives | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2015-12-29 | — | — | US | disclosed |
| US-20130045982-A1 | BENZAMIDE DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045982-A1 | BENZAMIDE DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2013-02-21 | — | — | US | disclosed |
| WO-2011079036-A1 | BENZAMIDE DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045982-A1 | BENZAMIDE DERIVATIVES | BAD, BAK1, BRDT | FFAR2 4139/4885MEN1 3145/4885LMNA 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.